Jemperli 500 mg Injection

Product Details

Jemperli 500 mg Injection contains Dostarlimab-gxly, a PD-1 inhibitor used in the treatment of endometrial cancer and other solid tumors with mismatch repair deficiency (dMMR) or microsatellite instability-high (MSI-H). It works by enhancing the body’s immune response to fight cancer cells more effectively.

Uses:

1. Endometrial Cancer

• Indicated for patients with advanced or recurrent endometrial cancer that is dMMR/MSI-H positive and has progressed despite prior treatments.

2. Solid Tumors with dMMR/MSI-H Mutations

• Used for treating other solid tumors with mismatch repair deficiency (dMMR) that have failed previous therapies and lack alternative treatment options.

How Jemperli 500 mg Works:

Dostarlimab is a monoclonal antibody that blocks PD-1 receptors, preventing cancer cells from evading immune attack. This helps the body’s immune system recognize and destroy cancer cells.

Common Side Effects:

• Fatigue
• Nausea
• Diarrhea
• Rash
• Immune-related adverse effects (inflammation of lungs, liver, or intestines)

Serious Side Effects (Seek Medical Attention):

• Severe immune reactions affecting the lungs, liver, or intestines
• Severe infusion reactions (fever, chills, breathing difficulty)
• Endocrine disorders (thyroid or adrenal gland dysfunction)

Key Features:

✔ PD-1 inhibitor immunotherapy that enhances the immune response.
✔ Used in dMMR/MSI-H endometrial cancer and solid tumors.
✔ FDA & EMA approved for advanced cancer treatment.
✔ Improves progression-free survival in eligible cancer patients.

Precautions:

⚠ Immune-Related Side Effects: Monitor for lung, liver, and thyroid issues.
⚠ Infusion Reactions: Close monitoring during administration.
⚠ Pregnancy & Breastfeeding: Avoid use due to potential fetal harm.

Frequently Asked Questions (FAQs):

1. What is Jemperli 500 mg Injection used for?
Jemperli is used for treating advanced endometrial cancer and solid tumors with dMMR/MSI-H mutations that have progressed despite prior treatments.

2. How is Jemperli administered?
It is given as an intravenous (IV) infusion under the supervision of a healthcare provider.

3. Can Jemperli be used in combination with other therapies?
In some cases, it may be combined with chemotherapy or other cancer treatments based on a doctor’s recommendation.

4. What should I do if I miss a dose?
Consult your doctor immediately to reschedule your dose.

5. How does Jemperli compare to other immunotherapies?
Jemperli targets PD-1, similar to drugs like Keytruda (Pembrolizumab) and Opdivo (Nivolumab) but is specifically approved for dMMR/MSI-H cancers.

References:

📌 FDA Approval of Jemperli
📌 European Medicines Agency (EMA) – Jemperli